aod9604 therapy AOD 9604 Peptide AOD-9604|221231-10-3|COA

Researchers conduct most studies in preclinical settings, collect limited human data, and have not yet determined long-term systemic effects

The compounds could potentially be combined, as their mechanisms do not overlap

Specifically, 3 mg of GH in 0.6 mL is approximately equivalent, on a molar basis, to 0.25 mg of AOD9604

Allometric scaling to humans is contested and not validated

Important Note on the Evidence Base Important note on the evidence base: The peer-reviewed 5-Amino-1MQ research literature consists of small-molecule medicinal-chemistry characterization (selectivity, potency, membrane permeability) and rodent in vivo work primarily in diet-induced obesity models

What specific benefits have preclinical studies observed for each compound in models of metabolic disease